ALPHAGAN^® P is contraindicated in patients receiving monoamine oxidase (MAO) inhibitor therapy. Although ALPHAGAN^® P ophthalmic solution had minimal effect on the blood pressure of patients in clinical studies, caution should be exercised in treating patients with severe cardiovascular disease. ALPHAGAN^® P should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, or thromboangiitis obliterans. As with other drugs in this class, ALPHAGAN^® P may cause fatigue and/or drowsiness in some patients. Caution in using concomitant drugs such as anti-hypertensive and/or cardiac glycosides is advised. Adverse events occurring in approximately 10% to 20% of the subjects included: allergic conjunctivitis, conjunctival hyperemia, and eye pruritus. Adverse events occurring in approximately 5% to 9% included: burning sensation, conjunctival folliculosis, hypertension, ocular allergic reaction, oral dryness, and visual disturbance.

If you have any questions, please ask your physician or refer to the Prescribing Information (PDF) on this page.